Advanced search
Publication Cover
Acta Oncologica Volume 50, 2011 - Issue 1
Journal homepage
1,626
Views
32
CrossRef citations to date
0
Altmetric
Research Article

A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)

Viktor Grünwald Medical School Hannover, Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Germany
,
Ingrid M. E. Desar Department of Medical Oncology, Radboud University Nijmegen Medical Centre, The NetherlandsCorrespondence[email protected]
,
John Haanen Netherlands Cancer Institute Amsterdam, The Netherlands
,
Walter Fiedler University Hospital Hamburg-Eppendorf, Germany
,
Ulrik Mouritzen NovoNordisk Bagsvaerd, Denmark
,
M. W. Brændholt Olsen NovoNordisk Bagsvaerd, Denmark
&
Carla M. L. van Herpen Department of Medical Oncology, Radboud University Nijmegen Medical Centre, The Netherlands
 show all
Pages 121-126 | Received 02 Apr 2010, Accepted 11 Jul 2010, Published online: 22 Dec 2010

Citations (32)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Elise Nassif, Constance Thibault, Yann Vano, Laure Fournier, Laetitia Mauge, Virginie Verkarre, Marc-Olivier Timsit, Arnaud Mejean, Eric Tartour & Stéphane Oudard. (2017) Sunitinib in kidney cancer: 10 years of experience and development. Expert Review of Anticancer Therapy 17:2, pages 129-142.
Read now
Shruti Bhatt, Kristopher A. Sarosiek & Izidore S. Lossos. (2017) Interleukin 21 – its potential role in the therapy of B-cell lymphomas. Leukemia & Lymphoma 58:1, pages 17-29.
Read now

Articles from other publishers (30)

Meichen Ma, Yuanyuan Xie, Jianhua Liu, Lina Wu, Yong Liu & Xiaosong Qin. (2024) Biological effects of IL-21 on immune cells and its potential for cancer treatment. International Immunopharmacology 126, pages 111154.
Crossref
Lucas Henrique Rodrigues da Silva, Luana Correia Croda Catharino, Viviane Jennifer da Silva, Gabriela Coeli Menezes Evangelista & José Alexandre Marzagão Barbuto. (2022) The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?. Biomedicines 10:2, pages 400.
Crossref
Rodion A. Velichinskii, Maria A. Streltsova, Sofya A. Kust, Alexander M. Sapozhnikov & Elena I. Kovalenko. (2021) The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. International Journal of Molecular Sciences 22:21, pages 11385.
Crossref
Salma B. Abdelbaky, Mayar Tarek Ibrahim, Hebatallah Samy, Menatalla Mohamed, Hebatallah Mohamed, Mahmoud Mustafa, Moustafa M. Abdelaziz, M. Laird Forrest & Islam A. Khalil. (2021) Cancer immunotherapy from biology to nanomedicine. Journal of Controlled Release 336, pages 410-432.
Crossref
Jessica S.W. Borgers & John B.A.G. Haanen. (2021) Cellular Therapy and Cytokine Treatments for Melanoma. Hematology/Oncology Clinics of North America 35:1, pages 129-144.
Crossref
Aviad Ben-Shmuel, Guy Biber & Mira Barda-Saad. (2020) Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?. Frontiers in Immunology 11.
Crossref
Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi & Doriana Fruci. (2020) Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. Frontiers in Immunology 10.
Crossref
Gaurav Nayyar, Yaya Chu & Mitchell S. Cairo. (2019) Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Frontiers in Oncology 9.
Crossref
Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa & Lorenzo Lo Muzio. (2018) Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients. BioMed Research International 2018, pages 1-16.
Crossref
Jiyu Ju, Lina Wang, Dalin Di, Weiling Xiao, Meiyu Peng, Yishuai Liu, Xiaoyan Fu, Chunling Zhao & Xuebin Qin. (2016) Adenovirus-mediated interleukin 21 gene transfer enhances antitumor immunity and reduces tumorigenicity of Hepa1–6 in mice. Oncology Letters 12:5, pages 3749-3754.
Crossref
Maria I. Carlo, Martin H. Voss & Robert J. Motzer. (2016) Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature Reviews Urology 13:7, pages 420-431.
Crossref
Viktor Grünwald. (2016) Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma. Oncology Research and Treatment 39:6, pages 353-358.
Crossref
Benjamin Carlisle, Nadine Demko, Georgina Freeman, Amanda Hakala, Nathalie MacKinnon, Tim Ramsay, Spencer Hey, Alex John London & Jonathan Kimmelman. (2016) Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. JNCI: Journal of the National Cancer Institute 108:1.
Crossref
Katarzyna Kamińska, Anna M. Czarnecka, Bernard Escudier, Fei Lian & Cezary Szczylik. (2015) Interleukin-6 as an emerging regulator of renal cell cancer. Urologic Oncology: Seminars and Original Investigations 33:11, pages 476-485.
Crossref
Theofanis Floros & Ahmad A. Tarhini. (2015) Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Seminars in Oncology 42:4, pages 539-548.
Crossref
Matthew WeinstockDavid F. McDermott. (2015) Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. American Society of Clinical Oncology Educational Book:35, pages e291-e297.
Crossref
Michela Croce, Valentina Rigo & Silvano Ferrini. (2015) IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology. Journal of Immunology Research 2015, pages 1-15.
Crossref
Suhendan Ekmekcioglu, Razelle Kurzrock & Elizabeth A. Grimm. 2015. The Molecular Basis of Cancer. The Molecular Basis of Cancer 789 808.e4 .
Han Hsi Wong & Tim Eisen. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma 177 205 .
Mayer Fishman. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma 441 467 .
Scott J. Antonia, James Larkin & Paolo A. Ascierto. (2014) Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clinical Cancer Research 20:24, pages 6258-6268.
Crossref
Shailender Bhatia, Brendan Curti, Marc S Ernstoff, Michael Gordon, Elisabeth I Heath, Wilson H Miller, Igor Puzanov, David I Quinn, Thomas W Flaig, Peter VanVeldhuizen, Kelly Byrnes-Blake, Jeremy A Freeman, Rachel Bittner, Naomi Hunder, Sonia Souza & John A Thompson. (2014) Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. Journal for ImmunoTherapy of Cancer 2:1.
Crossref
Geok Choo Sim & Laszlo Radvanyi. (2014) The IL-2 cytokine family in cancer immunotherapy. Cytokine & Growth Factor Reviews 25:4, pages 377-390.
Crossref
Rosanne Spolski & Warren J. Leonard. (2014) Interleukin-21: a double-edged sword with therapeutic potential. Nature Reviews Drug Discovery 13:5, pages 379-395.
Crossref
Audrey Thomas-Schoemann, Benoit Blanchet, Christophe Bardin, Gaëlle Noé, Pascaline Boudou-Rouquette, Michel Vidal & François Goldwasser. (2014) Drug interactions with solid tumour-targeted therapies. Critical Reviews in Oncology/Hematology 89:1, pages 179-196.
Crossref
Chang-cheng Zhao, Xi-qiang Gao, Jing Xue, Zhe Cong, Wei-lun Zhang, Ting Chen, Fang-xin Wu, Jing Xiong, Bin Ju, Aihua Su, Qiang Wei & Chuan Qin. (2013) Interleukin-21 up-regulates interleukin-21R expression and interferon gamma production by CD8+ cells in SHIV-infected macaques. Experimental Biology and Medicine 238:4, pages 400-409.
Crossref
XIU-CHENG PAN, LI LI, JUAN-JUAN MAO, WEI YAO, JUN-NIAN ZHENG, MEI LIU & JUAN-JUAN FU. (2013) Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma. Oncology Letters 5:1, pages 90-96.
Crossref
Bernard Escudier, Cezary Szczylik, Camillo Porta & Martin Gore. (2012) Treatment selection in metastatic renal cell carcinoma: expert consensus. Nature Reviews Clinical Oncology 9:6, pages 327-337.
Crossref
Anne Flörcken, Anna Takvorian, Antje Van Lessen, Anju Singh, Werner Hopfenmüller, Bernd Dörken, Antonio Pezzutto & Jörg Westermann. (2012) Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma. Anti-Cancer Drugs 23:3, pages 298-302.
Crossref
. (2011) Current World Literature. Current Opinion in Supportive & Palliative Care 5:3, pages 297-305.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.